Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 31053472
Li S, et al. (2019) Ca-Stimulated AMPK-Dependent Phosphorylation of Exo1 Protects Stressed Replication Forks from Aberrant Resection. Mol Cell 74, 1123-1137.e6 31053472
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.

S746-p - EXO1 (human)
Modsite: PGLYKSSsADSLSTT SwissProt Entrez-Gene
Orthologous residues
EXO1 (human): S746‑p, EXO1 (mouse): S737‑p
Methods used to characterize site in vivo immunoprecipitation, mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  HeLa (cervical), MEF (fibroblast), U2OS (bone cell)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Enzymes shown to modify site in vitro
Type Enzyme
KINASE Chk1 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Chk1 (human) activation of upstream enzyme, siRNA inhibition of enzyme, pharmacological inhibitor of upstream enzyme
KINASE AMPKA1 (mouse) phospho-antibody, activation of upstream enzyme, transfection of wild-type enzyme, pharmacological inhibitor of upstream enzyme, genetic knockout/knockin of upstream enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
hydroxyurea increase
aphidicolin increase
siRNA decrease Chk1-siRNA inhibits
compound_C hydroxyurea inhibit treatment-induced increase
AZD7762 hydroxyurea inhibit treatment-induced increase
AZD7762, compound_C hydroxyurea inhibit treatment-induced increase
CAMKK2 (human) increase
BAPTA-AM hydroxyurea inhibit treatment-induced increase
A23187 increase
thapsigargin increase
Downstream Regulation
Effect of modification (function):  molecular association, regulation
Effect of modification (process):  chromatin organization, altered, signaling pathway regulation
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
14-3-3 sigma (human) Induces co-immunoprecipitation
Comments:  Ca2+- CAMKK2-AMPK-Exo1 signaling pathway